Terms: = Uterine cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Clinical Outcome
4 results:
1. clinical impact of genetic alterations of ctnnb1 in patients with grade 3 endometrial endometrioid carcinoma.
Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
[TBL] [Abstract] [Full Text] [Related]
2. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome.
Hollis RL; Thomson JP; Stanley B; Churchman M; Meynert AM; Rye T; Bartos C; Iida Y; Croy I; Mackean M; Nussey F; Okamoto A; Semple CA; Gourley C; Herrington CS
Nat Commun; 2020 Oct; 11(1):4995. PubMed ID: 33020491
[TBL] [Abstract] [Full Text] [Related]
3. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the uterine Corpus are Characterized by ctnnb1 Mutations and Can Show Adverse clinical outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract] [Full Text] [Related]
4. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (ctnnb1) pathway are associated with independent primary tumors and favorable prognosis.
Irving JA; Catasús L; Gallardo A; Bussaglia E; Romero M; Matias-Guiu X; Prat J
Hum Pathol; 2005 Jun; 36(6):605-19. PubMed ID: 16021566
[TBL] [Abstract] [Full Text] [Related]
